Corbus Pharmaceuticals Holdings, Inc.
(NASDAQ : CRBP)

( )
CRBP After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Interested in Gold Updates?
Receive the latest updates on the gold and silver markets.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
MRNAModerna, Inc. 1.95%69.150.0%$1917.83m
NVAXNovavax, Inc. 9.93%146.5196.5%$1301.01m
SRNESorrento Therapeutics, Inc. -4.38%12.441.5%$767.50m
GILDGilead Sciences, Inc. 0.47%68.501.0%$580.36m
AMGNAmgen, Inc. 0.36%239.711.3%$465.88m
REGNRegeneron Pharmaceuticals, Inc. 0.28%612.572.7%$378.37m
VRTXVertex Pharmaceuticals, Inc. 0.05%267.291.9%$351.81m
BIIBBiogen, Inc. 0.32%289.451.4%$344.47m
ILMNIllumina, Inc. -1.69%347.563.5%$340.75m
BNTXBioNTech SE -3.32%68.640.0%$334.95m
ATNMActinium Pharmaceuticals, Inc. -1.21%9.7913.3%$231.53m
EBSEmergent BioSolutions, Inc. -1.09%133.476.4%$198.26m
VXRTVaxart, Inc. 0.55%9.140.0%$194.27m
MCRBSeres Therapeutics, Inc. -4.62%27.263.6%$181.12m
ALXNAlexion Pharmaceuticals, Inc. 1.06%102.971.9%$162.43m

Company Profile

Corbus Pharmaceuticals Holdings, Inc. is a phase 3 clinical-stage pharmaceutical company, which focuses on the development and commercialization of novel therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases. The Company's lead product candidate, lenabasum, is a novel, synthetic oral endocannabinoid-mimetic drug designed to resolve chronic inflammation and fibrotic processes. Lenabasum is currently being evaluated in systemic sclerosis, cystic fibrosis, dermatomyositis, and systemic lupus erythematosus. The company was founded on December 18, 2013 and is headquartered in Norwood, MA.